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Background: Haplotype-specific alternative splicing of the endoplasmic reticulum (ER)
aminopeptidase type 2 (ERAP2) gene results in either full-length (FL, haplotype A)
or alternatively spliced (AS, haplotype B) mRNA. HapA/HapA homozygous (HomoA)
subjects show a reduced susceptibility to HIV-1 infection, probably secondary to the
modulation of the antigen processing/presenting machinery. ERAP1 was recently shown
to be secreted from the plasma membrane in response to activation; we investigated
whether ERAP2 can be released as well and if the secreted form of this enzyme retains
its antiviral function.
Methods: Human monocyte derived macrophages (MDMs) were differentiated
from peripheral blood mononuclear cells (PBMCs) isolated from 6 HomoA healthy
controls and stimulated with IFNγ and LPS. ERAP2-FL secretion was evaluated
by mass spectrometry. PBMCs (14 HomoA and 16 HomoB) and CD8-depleted
PBMCs (CD8−PBMCs) (4 HomoA and 4 HomoB) were in vitro HIV-infected in the
absence/presence of recombinant human ERAP2-FL (rhERAP2) protein; p24 viral
antigen quantification was used to assess viral replication. IFNγ and CD69 mRNA
expression, as well as the percentage of perforin-producing CD8+ T Lymphocytes, were
analyzed 3 and 7-days post in vitro HIV-1-infection, respectively. The effect of rhERAP2
addition in cell cultures on T cell apoptosis, proliferation, activation, and maturation was
evaluated as well on 24 h-stimulated PBMCs.
Results: ERAP2 can be secreted from human MDMs in response to IFNγ/LPS
stimulation. Notably, the addition of rhERAP2 to PBMC and CD8−PBMC cultures
resulted in the reduction of viral replication, though these differences were statistically
significant only in PBMCs (p < 0.05 in both HomoA and HomoB). This protective
effect was associated with an increase in IFNγ and CD69 mRNA expression and
in the percentage of perforin-expressing CD107+CD8+ cells. RhERAP2 addition also
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resulted in an increase in CD8+ activated lymphocyte (CD25+HLA−DRII+) and Effector
Memory/Terminally differentiated CD8+ T cells ratio.
Conclusions: This is the first report providing evidence for the release of ERAP2 in
the secretome of immunocompetent cells. Data herein also indicate that exogenous
ERAP2-FL exerts its protective function against HIV-1 infection, even in HomoB subjects
who do not genetically produce it. Presumably, this defensive extracellular feature is only
partially dependent on immune system modulation.
Keywords: ERAP2, haplotype, HIV-1, MDM, secretion, immune system, CTL, IFNγ
INTRODUCTION
Endoplasmic reticulum aminopeptidase 2 (ERAP2) is an IFNγ-
and TNFα-inducible, ubiquitously-expressed, zinc-dependent,
ER-localized aminopeptidase that belongs to the M1 family
of aminopeptidases. It partakes in the antigen processing
pathway, hinging on the generation of peptide ligands for Major
Histocompatibility Class I (MHC-I) molecules (1). In Particular,
ERAP2 and the paralog ERAP1 protein are responsible for
trimming the N-terminal residue extensions of the antigenic
peptide precursors which are shaped in the cytosol by the
proteasome, resulting in the generation of the optimal N-
terminal for MHC I binding. Hence, ERAPs play a key role
in editing peptide quality and, in turn, cytotoxic T lymphocyte
(CTL) repertoire shaping and activation (1, 2), as indicated
by studies showing reduced CTL responses in ERAP-deficient
mice (3).
The haplotype network of ERAP2 is highly structured
with two differentiated haplogroups, hereafter referred to
as HapA and HapB. HapA leads to the expression of a 960
amino acid full-length protein (ERAP2-FL). Conversely,
HapB, harbors the T allele for rs2549782 (Asn392Lys) and
the G allele for rs2248374, which activates a cryptic splice
site in intron 10 and the production of an alternatively
spliced ERAP2 mRNA (ERAP2-AS) with two in-frame
stop codons. The preservation of the two haplogroups at
similar frequencies, around 0.5 in all populations, suggests
a functional difference between HapA and B (4). However,
the truncated version deems to be non-functional or partially
functional as it exhibits a reduced aminopeptidase activity
when tested in vitro using various aminoacyl-MCAs (5, 6).
Non-synonymous ERAP2 polymorphisms were initially found to
influence risk for several MHC-I-dependent diseases (ankylosing
spondylitis, birdshot chorioretinopathy, and psoriasis), as well
as susceptibility to different bacterial and viral infections (7–12).
We showed that the G allele of rs2549782, which tags HapA,
is associated with natural resistance to sexually-transmitted
HIV-1 infection, potentially as a result of balancing selection
through host-pathogen interactions (3, 10). Results so far
obtained indicate that these variants determine a different
expression of HLA-ABC on leucocytes (13, 14) and influence
the processing of HIV peptides originated from intracellular
processing, resulting in a unique repertoire of antigens
presented to CD8+ T lymphocytes and in a diverse vulnerability
to infection.
Besides its intracellular role, in vitro analyses demonstrated
that ERAP2, like ERAP1, may be involved in extracellular
biological processes, including promotion of angiogenesis and
blood pressure regulation, through their role in the cleavage
of bioactive peptide hormones in the renin-angiotensin system
(15). Themechanism by which ERAP2modulates these functions
is puzzling given that, as far as it is known, this enzyme is
only localized in the ER. Indeed, while ERAP1 secretion in
the extracellular milieu has been thoroughly documented in
immunocompetent cells (16, 17) and in murine macrophage cell
lines (12), ERAP2 release has been reported only in the secretome
of tumor cells derived from papillary thyroid carcinoma (18). The
release of ERAP1 is exosome-mediated and dependent on cellular
activation (19). Once secreted ERAP1 acts through a mechanism
that is essentially independent from antigen processing and
presentation and involves the proteolytic cutting of target
proteins, which results in the activation of effector functions such
as the phagocytic and NO synthetic activities of macrophages
(19–21). Accordingly, Goto and coworkers described ERAP1 as
a “moonlighting protein” acting as a final processing enzyme
of MHC class I-presented antigenic is the case peptides in the
ER, as well as a macrophage inductor in the extracellular milieu,
following secretion by inflammatory stimuli.
Given that ERAP1 and ERAP2 have similar contribution to
the field and a high sequence homology (22) that allows them
to function both as homodimers and heterodimers (2, 23), we
decided to clarify the following questions regarding ERAP2: (1)
can ERAP2 be secreted by immune-competent activated cells?
(2) If this is the case, does secreted ERAP2 retain its anti-HIV-
1 properties? (3) Does this antiviral function rely on immune
system modulation, even in the extracellular milieu?
MATERIALS AND METHODS
PBMC Isolation and Cell Culture
Whole blood from 50 Italian Healthy Controls (HCs) was
collected by venipuncture in Vacutainer tubes containing EDTA
(Ethylene diamine tetracetic acid) (BD Vacutainer, San Diego,
CA). Peripheral Blood Mononuclear Cells (PBMCs) were
isolated by density gradient centrifugation on Ficoll (Cedarlane
Laboratories Limited, Hornby, Ontario, Canada) and counted
with the automated cell counter ADAM-MC (Digital Bio,
NanoEnTek Inc., Korea), which allows for discrimination of
viable from non-viable cells. PBMCs isolated from 8 subjects (4
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HomoA and 4 HomoB) were incubated for 24-h with/without
recombinant human (rh) ERAP2, in order to analyse T cell
apoptosis, proliferation, activation, and maturation.
The Ethical Committee of the Don C. Gnocchi Foundation
IRCCS approved the study (Prot. N◦10/2018/CE_FdG/SA). All
the donors signed an informed consent form, in accordance with
the Declaration of Helsinki.
Genotyping Analyses
Total DNA extracted by DNA purification Maxwell R© RSC
Instrument (Promega) and quantified by the Nanodrop 2000
Instrument (Thermo Scientific) was used as a template for
PCR amplification using TaqMan probes specifically designed
to perform a SNP genotyping assay for rs2549782 (G/T)
(TaqMan SNP Genotyping Assay; Applied Biosystems, Foster
City, California, USA). Data were analyzed by using the allelic
discrimination real-time PCR method.
CD8+ T Cells Depletion by PBMCs
CD8+ T cells were isolated from PBMCs of 8 subjects (4
HomoA and 4 HomoB) by direct magnetic labeling using
CD8 microbeads (Miltenyi Biotech, Germany) according to
manufacturer’s protocol. CD8+ isolated T cells and CD8-
depleted PBMCs (CD8−PBMCs) were counted with the
automated cell counter ADAM-MC (Digital Bio). CD8−PBMC
purity, assessed by flow cytometry, range was always >95%.
CD8−PBMCs were used for in vitro HIV-1 infection assay
with rhERAP2.
Monocyte Isolation and Monocyte-Derived
Macrophages (MDMs) Differentiation
The percentage of CD14+monocytes was determined in PBMCs
isolated from 6 HomoA subjects by flow cytometer analyses.
MDMs were generated as previously described (24) incubating 1
× 106 adherent monocytes for 5 days in RPMI with 20% of Fetal
Bovine Serum (FBS) (Euroclone) and 100 ng/ml macrophage-
colony stimulating factor (M-CSF) (R&D Systems, Minneapolis,
USA). MDM differentiation was assessed by optical microscope
observation (Leitz Laborlux, Germany).
Cell Cultures and MDM Protein Extraction
One million MDMs isolated from 6 HomoA subjects were
cultured in RPMI (Sigma, Saint Louis, USA) with or without
IFNγ (100U) (R&D Systems, Minneapolis, USA) plus LPS
(1µg/mL) (Sigma, Saint Louis, USA) and incubated for 24 h at
37◦C with 5% CO2. At the end of the incubation period, MDMs
were dislodged by non-enzymatic cell dissociation solution
(SIGMA) according to manufacturer’s protocol and counted with
the automated cell counter ADAM-MC (Digital Bio). MDM
cellular proteins were then extracted by RIPA buffer (Sigma, Saint
Louis, USA) and stored at −80◦C together with the collected
supernatants for further analyses.
SDS-PAGE and in-gel Tryptic Digestion
MDM extracts and MDM media protein quantification was
assessed by BCA protein assay kit (Thermo Scientific Pierce).
Samples were sub-pooled (50 µg per pool), separated on a 8–
14%T SDS-PAGE (Hoefer) and stained with SyproRuby (Thermo
Fisher). Gel bands in the range of 105–120 KDa, identified
according to the HMW Calibration Kit (GE Healthcare),
were gel excised and processed for in-gel tryptic digestion.
Sequencing-grade modified porcine trypsin (5 ng/µL in 10mM
ammonium bicarbonate; Promega, Fitchburg, WI, USA) was
used for protein digestion at 37◦C, and the tryptic peptides were
extracted with acetonitrile, then concentrated and dried in the
vacuum concentrator.
LC-MS/MS Analysis
Peptide samples were reconstituted in HPLC buffer A (0.1%
formic acid) and separated on a Dionex UltiMate 3000 HPLC
System with an Easy Spray PepMap RSLC C18 column (150mm,
internal diameter of 75µm) (Thermo Scientific), adopting a four
steps ACN/formic acid gradient (8% ACN in 0.1% formic acid
for 5min, 8–40% ACN in 0.1% formic acid for 90min, 40–
90% ACN in 0.1% formic for 1min, 90% ACN for 15min, at
a flow rate of 0.3 µl/min), and electrosprayed into an Orbitrap
Tribrid Fusion (Thermo Fisher Scientific, Bremen, Germany).
The LTQ-Orbitrap was operated in positive mode in data-
dependent acquisition mode to automatically alternate between
a full scan (350–2,000 m/z) in the Orbitrap (at resolution 60000,
AGC target 1000000) and subsequent CID MS/MS in the linear
ion trap of the 20 most intense peaks from full scan (normalized
collision energy of 35%, 10ms activation). Isolation window: 3
Da, unassigned charge states: rejected, charge state 1: rejected,
charge states 2+, 3+, 4+: not rejected; dynamic exclusion
enabled (60 s, exclusion list size: 200). Mass spectra were analyzed
using MaxQuant software (version 1.6.3.3). The initial maximum
allowed mass deviation was set to 6 ppm for monoisotopic
precursor ions and 0.5 Da for MS/MS peaks. Enzyme specificity
was set to trypsin/P, and amaximumof twomissed cleavages were
allowed. Carbamidomethylation was set as a fixed modification,
while N-terminal acetylation and methionine oxidation were
set as variable modifications. The spectra were searched by the
Andromeda search engine against the Homo Sapiens Uniprot
sequence database (release 22.10.2018). Protein identification
required at least one unique or razor peptide per protein group.
Quantification in MaxQuant was performed using the built in
XIC-based label free quantification (LFQ) algorithm using fast
LFQ. The required false positive rate (FDR) was set to 1% at
the peptide, 1% at the protein and 1% at the site-modification
level, and the minimum required peptide length was set to 7
amino acids.
In vitro HIV-1 Infection Assay of
Recombinant Human (rh) ERAP2-Treated
PBMCs and CD8−PBMCs
Recombinant human (rh)-ERAP2 (R&D Systems, Minneapolis,
USA) resembles the full length ERAP2 variant and preserves the
same enzymatic activity in vitro (25). To assess the optimal dose
of rh-ERAP2 to be used in an in vitro HIV-1 infection assay, 2
× 106 PBMCs isolated from 3 GG (HapA) HCs were cultured in
RPMI 1640 containing FBS (20%) with or without different doses
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(10, 100, 1000 ng/ml) of rh-ERAP2 (R&D Systems, Minneapolis,
USA). After 3 h, 0.5 ng HIV-1Ba−L virus /1 × 10
6 cells were
added to each well and incubated for 24 h at 37◦C and 5% CO2.
Cells were then washed and re-suspended in medium containing
IL-2 (15 ng/ml) (R&D systems, Minneapolis, Minnesota, USA),
RPMI 1640, 20% FBS with/without different doses of rhERAP2
and incubated at 37◦C and 5% CO2. Every 2 days, cells were
supplemented with IL-2 and rhERAP2. p24 antigen ELISA
(XpressBio, Frederick, MD, USA) was performed on 6-day post
infection supernatants. After assessing the optimal dose to be
used (100 ng/ml), the same assay was performed on PBMCs (14
HapA and 16 HapB) and CD8−PBMCs (4 HapA and 4 HapB).
Furthermore, PBMCs were collected 3 and 6 days post infection
for mRNA expression and cytometric analyses, respectively.
Gene Expression Analysis
RNA analyses were made as previously described (26). cDNA
quantification for CD69 and IFNγ, (Bio-rad, CA, USA) was
performed by using a real-time PCR (CFX96 connect, Bio-rad,
CA, USA) and a SYBR Green PCR mix (Bio Rad), and all
reactions were run in duplicate. The results are presented as the
media of the relative expression units to the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and β-actin reference genes
calculated by the 2−11Ct equation using the CFX manager 3.1
(Bio Rad). Reactions were performed according to the following
thermal profile: initial denaturation (95◦C, 15min) followed
by 40 cycles of 15 s at 95◦C (denaturation) and 20 s at 60◦C
(annealing) and 20 s at 72◦C (extension). Melting curve analysis
was also analyzed for amplicon identification. Ct values of 35 or
higher were excluded from the analyses.
Immunofluorescent Staining
PBMCs were stained with Phycoerythrin-Cyanin-5 (PC5)-
labeled anti-CD4, Phycoerythrin-Cyanin-7 (PC7)-labeled
anti-CD8, PC7-labeled anti-CD14, PC5-labeled anti-CD25-,
CD45RA-, CD107A, Phycoerythrin (PE)-labeled anti-CCR7,
PE-labeled anti-HLA-DRII and Fluorescein Isothiocyanate
(FITC)-labeled anti-Annexin V specific mAbs for 30min at RT
in the dark, washed with PBS and fixed with 100µl of PFA (1%)
(BDH, UK). For the analysis of intracellular protein expressing
cells, PBMCs were washed, treated with Cell Permeabilization kit
(FIX & PERM kit, eBioscience) and incubated for 30min at 4◦C
in the dark with allophicocianine (APC)-labeled anti-Perforin
specific monoclonal antibodies.
Evaluation of Apoptosis
CD4-PC5 and CD8-PC7 stained cells were washed and
resuspended in ice-cold 1X Binding Buffer (Beckman-Coulter,
Fullerton, CA, USA) plus 10µl of Annexin V (AV) for 15 minutes
on ice in the dark. Finally, cell suspensions were resuspended in
400ul of 1X Binding Buffer and analyzed by flow-cytometry.
Carboxyfluorescein Diacetate Succinimidyl
Ester (CFSE) Proliferation
Cells were either left unstained as a control or stained with CFSE
(Cell-Trace CFSE Proliferation Kit, Molecular Probes, Invitrogen
technologies) to a final 10µM concentration with PBS, and
immediately incubated for 3min. Cells were then washed and
incubated RPMI-1640 culture media with 20% of human serum
and adjusted to a concentration of 1 million per ml. Cells were
then cultured unstimulated or were stimulated with 100ng/mL of
rhERAP2. After 5 days, the cells were harvested and the CFSE
signal of gated lymphocytes was analyzed by flow cytometry.
Cytometric Analysis
Analyses were performed using a Beckman-Coulter Gallios
flow-cytometer equipped with two lasers operating at 488
and 638 nm, respectively, interfaced with Gallios software and
analyzed with Kaluza v 1.2. Two-hundred thousand events were
acquired and gated on Forward and Side scatter properties
for lymphocyte. Data were collected using linear amplifiers for
forward and side scatter and logarithmic amplifiers for FL1,
FL2, FL4, FL5, and FL6. Samples were first run using isotype
control or single fluorochrome-stained preparations for color
compensation. Rainbow Calibration Particles (Spherotec, Inc.
Lake Forest, IL) were used to standardize results.
Statistical Analyses
Data were analyzed using Student’s T or ANOVA test by
GRAPHPAD PRISM version 5 (Graphpad software, La Jolla,
Ca, USA), and p-values of 0.05 or less were considered to
be significant.
RESULTS
ERAP2 Allelic Variants
Analysis of ERAP2 SNP prevalence in the selected
genes did not show any difference compared with
the European population distribution reported in
the U.S. National Library of Medicine Database
[https://www.ncbi.nlm.nih.gov/snp/rs2549782?fbclid=IwAR1Zd
wC747PDWvtAzt6hZBV5j7oFZiPkLjY-JdSee1Plzvym7fhJVQc1
Aks (Data not shown). Among the 50 genotyped subjects:
14 were HomoA, 20 heterozygous, 16 HomoB. Successive
analyses were performed only on PBMCs isolated from HomoA
and HomoB subjects to avoid confounding results, possibly
associated to the heterozygous genotype.
ERAP2 Is Secreted by LPS/IFNγ Stimulated
Human MDMs
As ERAP1 is released in the secretome of immunocompetent
cells following IFNγ and LPS stimulation, we hypothesized that
its paralog ERAP2 might also be secreted into the extracellular
milieu of activated MDMs. To this end, high resolution MS
analysis was conducted on both MDM supernatants and cellular
proteins after one-dimensional SDS PAGE, on gel bands close to
ERAP1 and ERAP2 molecular weight (107 and 110 KDa).
ERAP1 and ERAP2 expression was detected in both
unstimulated and stimulated MDM cellular extracts (Figure 1;
Figure S1; Table S1). Notably, co-stimulation of human MDMs
with IFNγ and LPS induced ERAP1 as well as ERAP2-secretion.
As expected, ERAP1 expression was higher compared to ERAP2
in all the conditions (27), and these differences reached statistical
significance in unstimulated cellular extracts (p< 0.02).
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FIGURE 1 | Label free quantitation (LFQ) intensity of ERAP2 and ERAP1 in
unstimulated and LPS/IFN-γ stimulated MDMs from HomoA subjects and in
related cell media. ERAP1 (white bars) was generally more expressed than
ERAP2 (gray bars), with a statistical p-value of 0.02 in unstimulated cells.
ERAP1 and ERAP2 were not secreted by unstimulated MDMs but only in
response to macrophage activation by LPS/ IFNγ. Mean values and SEM are
shown. *p < 0.05.
To exclude the possibility that ERAPs release was due to an
aspecific mechanism resulting from cell damage, the presence of
ERAP2 and ERAP1 proteins was also investigated in cell media
of unstimulated MDMs. Both proteins were totally absent in the
secretome of unstimulatedMDMs (Figure 1). These results show
for the first time that ERAP2 is secreted by cells and that its
secretion is a consequence of macrophage activation.
rhERAP2 Addition Reduces in vitro HIV-1
Infection in a Dose Dependent Manner in
PBMCs
We next evaluated whether rhERAP2 pre-treated PBMCs could
modulate viral susceptibility/replication in an in vitro HIV-1
infection assay.
Initial results obtained in a pilot study performed on PBMCs
from 3 HomoA subjects, demonstrated that rhERAP2 reduces
HIV-1 replication in a dose-dependent manner with a peak effect
using 100 ng/ml of the enzyme (Figure 2A) (p< 0.05).
Subsequently, PBMCs from 14 HomoA and 16 HomoB
subjects were HIV-1 infected in vitro in the absence/presence
of 100 ng/ml of rhERAP2. Six days after in vitro infection,
and confirming previously published results (28), p24 levels
were significantly lower in HomoA compared to HomoB PBMC
cultures in which rhERAP2 was not added to the culture medium
(p < 0.05). Remarkably, the addition of rhERAP2 drastically
reduced viral replication inHomoB cells (percentage of reduction
compared to cells cultured without rhERAP2: 48%; p < 0.03),
which do not genetically produce the full-length form of the
protein (Figure 2B). rhERAP2 could also further down-regulate
susceptibility to HIV-1 infection/replication in HomoA cells
(percentage of reduction compared to cells cultured without
ERAP2: 45%; p < 0.03) (Figure 2B), i.e., cells that naturally
produced the full-length form of the protein. These results
indicate that the antiviral properties of full-length ERAP2 are
additive and can be modulated.
Considering all the analyzed subjects independently of their
ERAP2 genotype, the protective effect exerted by rhERAP2 (>2-
fold p24 decrease) was observed in 21 out of 30 individuals
(Figure 2B). Thus, ERAP2-FL preserves its antiviral function
even when secreted in the extracellular milieu.
Finally, we further investigated CD8+ T cell role in rhERAP2-
treated PBMCs by replicating the in vitro HIV-1 infection assay
on CD8−PBMCs isolated from 8 subjects (4 HomoA and 4
HomoB) in the presence/absence of rhERAP2. Results showed
that even in the absence of CD8+ T cells, rhERAP2 addition
to cell cultures resulted in a partial reduction of p24 levels in
both HomoA and HomoB subjects (percentage of reduction
compared to cells cultured without rhERAP2: HomoA 21%,
HomoB 23%), however, these differences did not reach statistical
significance (Figure 2C). Such results suggest that the antiviral
effect mediated by rhERAP2 is partially dependent on CD8+ cell
activation but it also relies on the activation of other effector
mechanisms, which are maintained in CD8−PBMCs.
rhERAP2 Antiviral Activity Is Only Partially
Dependent on Cytotoxic Response
The antiviral activity of intracellular ERAP2-FL protein
presumably involves its ability to shape a peptide repertoire that
activates a quantitatively and/or qualitatively more advantageous
pool of CD8+ T cells. To verify whether even exogenous ERAP2
modulates CTL response, we analyzed IFNγ and CD69 mRNA
expression, which are routinely monitored as CTL’s effector and
activation markers, respectively.
IFNγ mRNA expression was significantly higher in HomoA
HCs independently of rhERAP2 addition (p< 0.03) (Figure 3A).
Exogenous addition of rhERAP2 to cell cultures resulted in
an upregulation of IFNγ mRNA expression in in vitro HIV-1
infected PBMCs of all the subjects enrolled in the study; this
increase was statistical significant in HomoB cells alone (p <
0.001) (Figure 3A).
CD69 expression level was comparable in rhERAP2-untreated
PBMCs of HomoA and HomoB individuals; exogenous addition
of rhERAP2 to cell cultures significantly increased CD69
expression in both HomoA and HomoB cells (p < 0.05 in both
cases) (Figure 3B).
ERAP1 treatment significantly increased levels of cytotoxic
cell activation, as evidenced by increased CD107α expression
(29). Notably, in our study, perforin-producing CD107+CD8+
cells in untreated cultures were slightly increased in HomoA
compared to HomoB cells, although these differences did not
reach statistical significance (Figure 4). As shown in Figure 4,
in HomoA subjects, no significant differences were observed in
CD107+CD8+ cytotoxic T lymphocytes after exogenous addition
of rhERAP2 to cell cultures. Conversely, in HomoB individuals,
the addition of rhERAP2 to cell cultures resulted in a significant
increase of perforin-producing CD107+CD8+ cells.
These results indicate that the antiviral activity of extracellular
ERAP2-FL protein is partially dependent on activation of cell-
mediated immune response, mainly in those subjects who do not
genetically produce a functional ERAP2 protein.
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FIGURE 2 | Susceptibility to in vitro HIV-1 infection was reduced in peripheral blood mononuclear cells (PBMCs) and CD8-depleted PBMCs (CD8−PBMCs) treated
with recombinant human ERAP2 (rhERAP2). (A) PBMCs from 3 subjects were treated with different doses of rhERAP2 (10, 100, 1,000 ng/ml) and in vitro infected with
a R5 HIV1Ba-L. (B) PBMCs from 14 HomoA and 16 HomoB individuals were untreated (white bars) or treated (gray bars) with 100 ng/ml of rhERAP2 and in vitro
infected with a R5 HIV1Ba-L. (C) CD8−PBMCs from 4 HomoA and 4 HomoB individuals were untreated (white bars) or treated (gray bars) with 100 ng/ml of rhERAP2
and in vitro infected with a R5 HIV1Ba-L. P24 concentration was measured by ELISA 6 days post in vitro HIV-1 infection supernatants in all the experiments. Mean
values and SEM are shown. *p < 0.05; **p < 0.01.
FIGURE 3 | mRNA expression of interferon-γ (IFNγ) and CD69 was increased in in vitro rhERAP2-treated HIV-1 infected PBMCs. IFNγ (A) or CD69 (B) mRNA
expression in rhERAP2 untreated (white bars) or treated (gray bars) PBMCs from HomoA and HomoB subjects 3 days after in vitro HIV-1 infection. Mean values and
SEM are shown. *p < 0.05; **p <0.01.
rhERAP2 Effect on T Cell Apoptosis,
Proliferation, Activation, and Maturation
Since the antiviral activity of extracellular rhERAP2-FL protein
seems to be partially dependent on activation of cell-mediated
immune response, we next investigated the effect exerted by
rhERAP2 on T cell apoptosis, proliferation, activation and
maturation following PBMC incubation with/without rhERAP2
for 24 h. Analyses were performed on 4 HomoA and 4
HomoB subjects.
T Cell Apoptosis
rhERAP2 did not induce apoptosis either in CD4+or in CD8+
T cells as CD4+AV+ and CD8+AV+ cells were comparable in
untreated and rhERAP2-treated conditions. Moreover, even after
dividing the enrolled subjects according to their genotype, we did
not observe any effect on apoptosis induction (Figure S2).
T Cell Proliferation
No differences were observed in untreated and rhERAP2-treated
CD4+ and CD8+ T cell proliferation. This result suggests that the
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FIGURE 4 | The percentage of perforin-expressing CD107+CD8+ cells was
increased in in vitro rhERAP2-treated HIV-1 infected PBMCs. Percentage of
perforin-expressing CD107+CD8+ cells in rhERAP2 untreated (white bars) or
treated (gray bars) PBMCs from HomoA and HomoB subjects 3 days after in
vitro HIV-1 infection. Mean values and SEM are shown. *p < 0.05.
antiviral mechanism exerted by rhERAP2 does not depend on the
modulation of possible target cell’s replication (Figure S3).
T Cell Activation
Following rhERAP2 stimulation, the percentage of CD25+HLA-
DRII+CD4+ T cells was slightly increased in both HomoA
and HomoB cells, although not significantly (Figure 5A).
Conversely, the percentage of CD25+HLA-DRII+CD8+ T cells
was significantly increased in both Homo A (p < 0.01) and
HomoB (p< 0.03) subjects (Figure 5B).
T Cell Maturation
No differences were observed in the percentage of CD4+
Naïve (TN: CD45RA+CCR7+), CD4+ Central Memory
(CM: CD45RA−CCR7+), CD4+ Effector Memory (EM:
CD45RA−CCR7−) and CD4+ effector memory re-expressing
CD45RA (TEMRA: CD45RA+CCR7−) T cells. Conversely,
CD8+ T cell maturation was affected by rhERAP2 treatment.
In particular, the percentage of TEMRA CD8+ T cells
was significantly reduced in both HomoA (p<0.03) and
HomoB subjects (p < 0.05) following rhERAP2 treatment
(Figure 6A). As a consequence, the ratio between EM and
TEMRA CD8+ T cells was significantly increased in rhERAP2
treated PBMCs (Figure 6B).
DISCUSSION
There is a strong body of evidences highlighting that ERAP1 and
ERAP2 play a fundamental role in precursor peptide proteolysis
within the ER, which represents their natural domicile. However,
as these aminopeptidases are involved in other biological
processes, such as shedding of cytokine receptors, post-natal
angiogenesis, and regulation of blood pressure (9), the overall
subcellular localization of ERAPs remains debatable (15, 29).
Recent results indicated that ERAP1 can be localized in the
cytosol (30), at the cell membrane as a type II integral membrane
protein (31), and can be released from the cell following
appropriate activation (20, 32). Therefore, ERAP1 exhibits an
outstanding adaptability in terms of subcellular localization,
which is mainly conditioned by the cell type expressing it and
by the environmental stimuli triggering the cell (i.e., stress
response). As for ERAP2, a multidisciplinary integrated analysis
revealed its overexpression, along with other candidate genes,
in papillary thyroid carcinoma (PTC) and the cystic fluid
counterpart, pointing out a possible translocation from the
canonical ER localization (18). However, as tumor cells are by
definition genetically unstable and the cancer secretome may
significantly differ from that of the physiological counterpart
(32), to our knowledge this is the first report demonstrating
ERAP2 secretion by immunocompetent cells.
Notably, ERAP2, likewise ERAP1 could be detected only in
media of MDMs triggered by inflammatory stimuli, indicating
that the secretion of these proteins is a tightly controlled process
which is activated exclusively in response to a specific input.
The molecular mechanism leading to ERAP2 secretion in vivo
will need to undergo specific analyses. Previous studies focusing
on ERAP1 nevertheless allow some speculations. Thus, ERAP1
does not possess any classical ER localization signal and its
retention in the ER depends on the interaction with Erp44, an
ER resident protein disulfide isomerase, through the formation
of a mixed disulfide bond with a cysteine residue in the exon
10 loop (33). This interaction was shown to be important for
regulating ERAP1 retention and secretion, and in that context, in
controlling blood pressure through angiotensin II cleavage (33).
As ERAP2 lacks an ER retention signal as well and its exon 10
has a crystallography structure similar to that of ERAP1 (34),
its secretion might be promoted similarly to what is described
for ERAP1. However, to our knowledge, an interaction between
ERAP2 and ERp44 has not yet been demonstrated and further
analyses are needed to disclose the molecule/s holding ERAP2
in the ER. Furthermore, in line with ERAP1, it is also possible
to assume that two signals are required for the secretion of
ERAP2. The first one, represented by IFNγ, is responsible for
the synthesis and accumulation of the aminopeptidases within
the ER but not for their release, as it probably modifies the
amount and/or composition of the ER retention machinery of
ERAPs. The second one, provided by LPS, delivers the stress
signal indispensable to induce ERAP secretion and possibly their
extracellular activation.
In the attempt to investigate the biological functions of ERAP2
in the secretome, we first verified if its anti-HIV activity, recently
associated to the intracellular counterpart (28), is preserved
even in the extracellular milieu. Notably, results showed that
the addition of rhERAP2 to the in vitro HIV-1 infection assay
significantly reduced HIV-1 replication not only in HomoA,
but also in HomoB cells, that do not genetically produce it.
The mechanism by which exogenous ERAP2 interferes with
HIV-1 infection/replication is under investigation. However, the
analyses so far performed suggest that addition of rhERAP2 to
PBMCs did not affect CD4+ and CD8+ T cell proliferation and
apoptosis but, conversely, resulted in an increased activation of
T cells, mainly CD8+CD25+DRII+, as well as in a decreased
percentage of TEMRA CD8+ T cells in both HomoA and
HomoB subjects. As a consequence, the ratio between EM
and TEMRA CD8+ T cells was significantly increased in
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FIGURE 5 | The percentage of CD25+HLA-DRII+CD8+ was increased in in vitro rhERAP2-treated PBMCs. CD25+HLA-DRII+CD4+ T cells (A) or
CD25+HLA-DRII+CD8+ T cells (B) in 24 h-rhERAP2 untreated (white bars) or treated (gray bars) PBMCs from 4 HomoA and 4 HomoB subjects. Mean values and
SEM are shown. *p < 0.05.
FIGURE 6 | The percentage of CD8+ effector memory re-expressing CD45RA (TEMRA: CD45RA+CCR7−) T cells was reduced in in vitro rhERAP2-treated PBMCs.
(A) Percentage of CD8+ TEMRA in 24 h-rhERAP2 untreated (white bars) or treated (gray bars) PBMCs from 4 HomoA and 4 HomoB subjects. (B) Ratio between EM
(Effector Memory CD45RA−CCR7−) and TEMRA CD8+ T cells in 24 h-rhERAP2 untreated (white bars) or treated (gray bars) PBMCs from 4 HomoA and 4 HomoB
subjects. Mean values and SEM are shown. *p < 0.05.
rhERAP2 treated PBMCs, suggesting a reduced differentiation
of central memory CD8+ T cells into TEMRA in favor of EM.
Although the molecular mechanism(s) responsible for the effect
of rhERAP2 on CD8+ T cell maturation need to be further
investigated, we can speculate on the antiviral effect resulting
from this altered CD8+ T cell maturation. Thus, both EM
and TEMRA cells strongly express genes involved in CD8+ T
cell effector function, but EM cells have a greater expansion
potential, as well as increased IL-2 and IFNγ production, than
TEMRA ones (35, 36). Moreover, while TEMRA are short
lived cells that can no longer differentiate further to adopt
another identity, EM cells can revert to long-lived memory
cells, which are key for protecting the individual from severe
reinfection (37). Furthermore, mRNA expression of the T cell
activation marker CD69, the effector molecule IFNγ and the
percentage of perforin-expressing CD8+ T cells significantly
increased following rhERAP2 addition to in vitroHIV-1 infected
PBMCs. As mitogen-activated protein (MAP) kinases have
been implicated in many CD8+ T cell physiological processes,
including cell proliferation, differentiation, and death (38) and
p38MAP kinase regulates IFNγ production in CD8+T cells (39),
the investigation of T cellMAP kinase signalosome is necessary to
further clarify the ERAP2-HIV-infection axis. Interestingly, this
feature was definitely more evident in subjects who are not able
to genetically synthetize ERAP2 (HomoB subjects), presumably
following rhERAP2 internalization and re-localization into the
ER, where it compensates for the natural absence of the protein.
Conversely, rhERAP2-mediated inhibition of in vitro HIV-1
infection was clearly more potent in HomoA cells, in whom
rhERAP2 administration resulted in a moderate CTL activation.
Notably, HIV replication was reduced by rhERAP2 addition even
in CD8+ T cells- depleted cultural conditions. These results
suggest that, even if CD8+ T cells play a pivotal role in mediating
the antiviral effect of ERAP2, such an effect also relies on the
activation of other effector mechanisms, which are maintained
in CD8−PBMCs.
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FIGURE 7 | The cellular localization and functions of ERAP2. (A) Intracellular ERAP2 plays a key role in editing peptide quality and, in turn, cytotoxic T lymphocyte
(CTL) repertoire shaping and activation. (B) Following interferonγ (IFNγ) and lipopolysaccharides (LPS) stimulation ERAP2 may be released in the secretome of
immune competent cells where it interferes with HIV-1 replication through direct or indirect mechanisms, possibly involving macrophage activation. ER, Endoplasmic
Reticulum; MHC-I, Major Histocompatibility Complex class I; TCR, T Cell Receptor.
As a whole, these data suggest a scenery in which exogenous
ERAP2 antiviral function relies on two independent but
addictive mechanisms (Figure 7). Thus, extracellular ERAP2
may be partially endocytosed by the cells, where it displays
its canonical function in immune system modulation. This
protein, however, can also interact with extracellular substrates
resulting in the stimulation of antiviral pathways that are
only partially identified (6). In this context, some information
may derive from previous data obtained by analyzing ERAP1.
Thus, ERAP1, once secreted by different cell lines (i.e., COS-
7, RAW264.7 cells), is able to trim unpredictable molecules,
contributing to the activation of a signaling cascade but not
necessarily associated with the immune system. Hattori et al.,
for example, proved an efficient ERAP1 cleavage activity of
angiotensin II to angiotensin III and IV (16). “Bystander
cells” activation could also contribute to mediate recERAP2
antiviral function. Indeed, secreted ERAP1was shown to enhance
macrophage phagocytosis (20) and nitric oxide (NO) synthesis
by trimming peptides with N-terminal arginine (Arg) residues
(21). Since ERAP2 shows a strong preference for basic arginine
residue trimming (2) and supplies of free-Arg are essential
for maximum NO synthesis (21), it is tempting to speculate
that stressor-induced ERAP2 secretion could have direct and
indirect effects on macrophage activation, or more broadly on
pro-inflammatory response. This, in turn, could constitute a
favorable environment, raising an immune barrier that could
interfere with HIV entry, as suggested by several studies
portraying the profile of subjects who naturally resist HIV-1
infection (40–46).
Open questions concerning, among others, ERAP1
and ERAP2 dimerization in the secretome, as well as the
identification of the substrates recognized by ERAP2 within
the ER and in the extracellular milieu, require additional
researches. However, the putative relevance of ERAP2
secretion should not be underestimated. This finding poses
the premises to further investigate the role of ERAP2 in
both innate and adaptive immunostimulatory pathways, and
suggests that ERAP2 can promote inflammation via alternative
mechanisms in addition to its well-characterized antigen
processing function.
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